• Jaeho Jung
  • Vice President
  • ABL Bio

Curriculum Vitae

Education

Konkuk University, B.S. (Biology)
Konkuk University, M.S. (Microbiology)
Ohio State University, Ph.D. (Immunology)
Stanford University, Postdoctoral Fellow
Ochsner Clinic Foundation, Postdoctoral Fellow

Professional Experience

Biogen Idec, Scientist II (Antibody Discovery and Tumor Immunology)
HepaHope, R&D Director (Xenotransplantation)
Agensys (an affiliate of Astellas), Principal Scientist (In Vivo Pharmacology)
ABL Bio, Vice President (Discovery and In Vivo Pharmacology)

Research Interests

Development of Immuno-Oncology Therapeutics
Development of Antibody Based Therapeutics

Honors & Awards

-

Publications

-

Abstract

The Next Frontier of Cancer Immunotherapy by Bispecific Antibody

Immune check points have become the major cancer therapies as powerful and promising strategy to stimulate antitumor T cell activity. Cancer immunotherapy using immune-checkpoint blockade created a major paradigm shift in the treatment of advanced-stage cancers. Recent clinical trials have demonstrated significant response rates with anti-CTLA-4 and anti-PD-1 or PD-L1 antibodies in patients with late stage melanoma and squamous cell lung cancer.

The combination strategy of immunotherapeutic antibodies for treatment of cancer patients has shown benefits over single agent treatment. For example, combining anti-PD-1 antibodies to anti-CTLA-4 treatment in advanced melanoma patients has increased objective response rates. Bispecific antibodies (BsAbs) are an alternative option for the treatment of certain types of cancer. These BsAbs are composed of parts of two different monoclonal antibodies, allowing for dual binding and specificity to two different antigens. Recent progress in bispecific antibody technologies and the clinical success of a first generation bispecific T-cell engager (BiTE) antibody against CD19 resulted in major breakthrough for the next generation of T-cell redirecting bispecific antibodies.

ABL Bio is developing novel bispecific antibody, which can redirect effector T cells for the targeted killing of tumor cells. ABL Bio’s BsAb binds to target antigen on tumor cells in tumor microenvironment and stimulate signal on T cells by inducing INF-gamma. The present study shows that BsAb can induce T-cell activation and proliferation in the presence of target tumor cells, redirect potent T-cell mediated killing of target tumor cells in vitro system, and inhibit growth of tumors in vivo.